Bamlanivimab, administered with etesevimab receives FDA emergency use authorization for COVID-19
The specific approval for this monoclonal antibody is for treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalisation in patients.
Source:
Biospace Inc.